In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4949-4952

  Bowker, Karen E ^a   Caspers, Patrick ^b   Gaucher, Bérengère ^b   MacGowan, Alasdair P ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BAL 0030543; BAL 0030544; BAL 0030545; DIHYDROFOLATE REDUCTASE INHIBITOR; LINEZOLID; METICILLIN; MINOCYCLINE; MOXIFLOXACIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; IN VITRO STUDY; LISTERIA MONOCYTOGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS MITIS; STREPTOCOCCUS PNEUMONIAE;

FOLIC ACID ANTAGONISTS; GRAM-POSITIVE BACTERIA; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PHTHALAZINES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 70350318134     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00845-09     Document Type: Article

References (12)

1. Bowker, K., and A. P. MacGowan. 2008. The comparative activity of dihydrofolate reductase inhibitors BAL0030543, BAL 30555 and BAL0030545 against clinical strains of Gram-positive pathogens from the UK, abstr. F1-3936. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother.
2. Clark, C., L. M. Ednie, et al. 2009. Dihydrophthalazine antifolates, a family of novel antibacterial drugs: in vitro activities against diverse bacterial pathogens. Antimicrob. Agents Chemother. 53:1353-1361.
3. Clinical and Laboratory Standards Institute. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard. Document M7-A6. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical Laboratory Standards Institute. 2009 Performance standards for antimicrobial susceptibility testing; 18th informational supplement, vol.29, no.3. Document M100-S19. Clinical Laboratory Standards Institute, Wayne, PA.
5. Ednie, L. M., K. A. Smith, et al. 2007. Dihydrophthalazine anti-folates, a family of novel antibacterial drugs: in vitro activities against MSSA and MRSA, abstr. F1-934. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
6. Hawser, S., S. Lociuro, and K. Islam. 2006. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. 71:941-948.
7. Hitchings, G. H., and J. J. Burchall. 1965. Inhibitors of folate biosynthesis and function as a basis for chemotherapy. Adv. Enzymol. Relat. Areas Mol. Biol. 27:417-468.
8. Lin, G., L. M. Ednie, et al. 2008. Antistaphylococcal activities of dihydrophthalazine dihydrofolates, a family of novel antibacterial drugs by time-kill, abstr. F1-3937. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother.
9. Peppard, W. J., and C. D. Schuenke. 2008. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic resistant staphylococcal infections. Curr. Opin. Investig. Drugs 9:210-225.
10. Perez, F., R. A. Salata, and R. A. Bonomo. 2008. Current and novel antibiotics against resistant Gram positive bacteria. Infect. Drug Resist. 1:27-44.
11. Shapiro, S., L. Thenoz, et al. 2007. Dihydrophthalazine antifolates, a family of novel antibacterial drugs: in vitro activities against diverse bacterial pathogens, abstr. F1-933. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
12. Wootton, M., R. A. Howe, et al. 2001. A modified population analysis profile (PAP) method to detect Staphylococcus aureus with decreased susceptibility to vancomycin in a U. K. hospital. J. Antimicrob. Chemother. 47:399-403.